ALPRAZOLAM Drug Interactions
Also known as: Alprazolam
Alprazolam is a benzodiazepine medication used to treat anxiety disorders, including generalized anxiety disorder and panic disorder. It works by affecting certain natural chemicals in the brain to produce a calming effect. This helps reduce feelings of anxiety and panic.ALPRAZOLAM has 12 documented drug interactions in our database, including 2 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
2
Contraindicated
10
Major
0
Moderate
0
Minor
The primary clinical effects include profound sedation, respiratory depression (leading to hypoventilation and apnea), hypotension, and psychomotor impairment. This can rapidly progress to coma and death due to respiratory arrest, particularly in opioid-naïve individuals or those with underlying respiratory conditions.
Mechanism
Oxycodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), causing CNS depression, analgesia, and respiratory depression. Alprazolam is a benzodiazepine that enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, leading to increased CNS depression. The co-administration of these two CNS depressants results in an additive and synergistic depressant effect on the brainstem respiratory centers and overall CNS function.
Clinical Management
Concomitant use of oxycodone and alprazolam should be avoided due to the high risk of severe adverse outcomes, including death. If co-administration is absolutely necessary and no alternatives exist, prescribe the lowest effective doses for the shortest possible duration, closely monitor for respiratory depression and sedation, and educate patients and caregivers on the risks. Naloxone should be readily available.
The combination of tramadol and alprazolam can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment. This interaction significantly increases the risk of accidental overdose and life-threatening respiratory events.
Mechanism
Tramadol, an opioid analgesic, and alprazolam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. Opioids primarily activate mu-opioid receptors, leading to analgesia and respiratory depression, while benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at GABA-A receptors, resulting in sedation and anxiolysis. The co-administration of these agents leads to an additive and synergistic depression of the CNS, significantly increasing the risk of severe adverse outcomes.
Clinical Management
Concomitant use of tramadol and alprazolam is contraindicated due to the high risk of respiratory depression and death, as highlighted by an FDA Black Box Warning. If co-administration is unavoidable, the lowest effective doses should be used for the shortest possible duration, and patients must be closely monitored for signs of respiratory depression and sedation. Consider alternative non-opioid or non-benzodiazepine therapies, or taper one or both medications if already on combination therapy.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, hypoxemia, altered mental status, somnolence, and psychomotor impairment. These effects can be life-threatening and require immediate medical intervention.
Mechanism
Buprenorphine, an opioid partial agonist, and alprazolam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. Buprenorphine acts primarily on mu-opioid receptors, while alprazolam enhances the inhibitory effects of gamma-aminobutyric acid (GABA) at GABA-A receptors. The concomitant use leads to synergistic CNS depression, exacerbating effects on respiratory drive and consciousness.
Clinical Management
Avoid concomitant prescribing of buprenorphine and alprazolam whenever possible. If co-prescribing is unavoidable and alternative treatments are inadequate, use the lowest effective doses and shortest possible duration. Closely monitor patients for signs of respiratory depression and sedation, and educate them and their caregivers on these risks, including the availability of naloxone.
The concurrent use of fentanyl and alprazolam significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate and depth, hypoxemia, altered mental status, somnolence, and psychomotor impairment. These effects can be life-threatening and require immediate medical intervention.
Mechanism
Fentanyl, an opioid agonist, binds to mu-opioid receptors in the central nervous system (CNS), leading to dose-dependent CNS depression, including respiratory depression. Alprazolam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, also causing CNS depression. The co-administration of these two CNS depressants results in an additive and synergistic depressant effect on the brainstem respiratory centers and overall CNS function.
Clinical Management
Avoid concomitant use of fentanyl and alprazolam whenever possible due to the high risk of severe adverse outcomes. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest possible duration, monitor patients closely for signs of respiratory depression and sedation, and educate patients and caregivers about these risks. Have naloxone readily available for opioid overdose reversal.
Patients may experience severe respiratory depression, characterized by decreased respiratory rate and depth, hypoxemia, and hypercapnia. Profound sedation, stupor, coma, and death are significant risks. Other effects include increased risk of accidental overdose, psychomotor impairment, and hypotension.
Mechanism
Morphine, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Alprazolam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors. The synergistic CNS depressant effects of these two drug classes lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
Concomitant use of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse outcomes, as highlighted by an FDA Black Box Warning. If co-prescription is unavoidable, use the lowest effective doses for the shortest possible duration, closely monitor for respiratory depression and sedation, and educate patients and caregivers on the risks. Consider naloxone co-prescription for at-risk patients.
Co-administration of oxycodone and alprazolam can lead to profound sedation, respiratory depression, coma, and death. This interaction significantly increases the risk of life-threatening adverse effects due to additive central nervous system (CNS) depressant effects.
Mechanism
Oxycodone is an opioid agonist that causes CNS depression, while alprazolam is a benzodiazepine that enhances the effect of GABA, leading to further CNS depression. The combined pharmacodynamic effects result in additive respiratory and CNS depressant activity.
Clinical Management
Avoid concomitant use of oxycodone and alprazolam. If co-prescription is unavoidable, use the lowest effective doses for the shortest possible duration, and monitor patients closely for signs of respiratory depression and sedation. Consider alternative treatments that do not interact.
The concomitant use of codeine and alprazolam significantly increases the risk of severe CNS depression, including profound sedation, respiratory depression, coma, and death. Patients may experience slowed or difficult breathing, excessive drowsiness, dizziness, and unresponsiveness.
Mechanism
Codeine is an opioid analgesic that acts as an agonist at mu-opioid receptors, leading to central nervous system (CNS) depression, including respiratory depression and sedation. Alprazolam is a benzodiazepine that enhances the effect of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the CNS, resulting in an additive depressant effect on the CNS and respiratory drive.
Clinical Management
Concomitant use of opioids and benzodiazepines should generally be avoided due to the FDA Black Box Warning. If co-prescription is absolutely necessary, use the lowest effective doses for the shortest possible duration, monitor patients closely for signs of respiratory depression and sedation, and educate patients and caregivers on these risks. Consider alternative therapies that do not involve co-prescribing these drug classes.
Patients may experience severe respiratory depression, profound sedation, coma, and death. Other symptoms include dizziness, lightheadedness, impaired psychomotor function, and hypotension. The risk of overdose is significantly increased.
Mechanism
Both methadone, an opioid analgesic, and alprazolam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, primarily by enhancing GABAergic neurotransmission (benzodiazepines) and acting on mu-opioid receptors (methadone), resulting in profound respiratory depression and sedation.
Clinical Management
Avoid co-prescription of methadone and alprazolam whenever possible. If concurrent use is unavoidable, prescribe the lowest effective doses for the shortest possible duration, closely monitor for signs of respiratory depression and sedation, and educate patients and caregivers on these risks. Consider naloxone co-prescription and ensure patients understand its use.
The combination can lead to severe adverse effects including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, hypotension, and psychomotor impairment.
Mechanism
Both hydromorphone (an opioid agonist) and alprazolam (a benzodiazepine) are central nervous system depressants. They act synergistically to enhance GABAergic neurotransmission, leading to profound CNS depression. This combined effect significantly depresses the respiratory drive and reduces consciousness.
Clinical Management
Concomitant use should be avoided whenever possible. If co-prescription is unavoidable, use the lowest effective doses and shortest possible duration. Closely monitor patients for signs of respiratory depression and sedation, and provide naloxone for opioid overdose reversal. Educate patients and caregivers about the risks.
Patients may experience severe respiratory depression, profound sedation, coma, and potentially death. Other symptoms include dizziness, confusion, psychomotor impairment, and hypotension. The risk of these adverse effects is significantly increased when these drugs are used concomitantly.
Mechanism
Both oxymorphone (an opioid agonist) and alprazolam (a benzodiazepine) are central nervous system (CNS) depressants. Oxymorphone acts primarily on mu-opioid receptors, while alprazolam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors. The synergistic CNS depressant effects lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
Concomitant use should generally be avoided due to the high risk. If co-prescription is absolutely necessary and no alternatives exist, use the lowest effective doses for the shortest possible duration, and closely monitor patients for respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms, and consider prescribing naloxone for overdose reversal.
The combination can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, slowed or shallow breathing, hypoxia, and hypotension. These effects can be rapid in onset and life-threatening.
Mechanism
Tapentadol, an opioid analgesic, acts as a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, causing central nervous system (CNS) depression. Alprazolam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors, leading to further CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of adverse outcomes.
Clinical Management
Avoid concomitant use of opioids and benzodiazepines whenever possible. If co-prescription is unavoidable, use the lowest effective doses and shortest possible duration. Closely monitor patients for signs of respiratory depression and sedation, and educate them and their caregivers on these risks. Consider prescribing naloxone for at-risk patients.
Concomitant use of hydrocodone and alprazolam can lead to profound sedation, respiratory depression, coma, and death. This combination should generally be avoided due to the increased risk of life-threatening adverse effects.
Mechanism
Both hydrocodone (an opioid) and alprazolam (a benzodiazepine) are central nervous system depressants. Their co-administration results in an additive pharmacodynamic depressant effect on the CNS, particularly on the respiratory drive.
Clinical Management
Avoid concomitant use whenever possible. If co-prescription is unavoidable, limit dosages and duration to the minimum necessary, and monitor patients closely for signs of respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms to watch for.
For complete prescribing information:
View full ALPRAZOLAM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.